Skip to content

US · IXHL · BIOTECHNOLOGY

Incannex Healthcare Limited (IXHL) intrinsic value and stock valuation

$1.86as of 2026-11-21 · Mkt cap 36.85M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Incannex Healthcare Limited DCF and intrinsic value

InvestorsCraft values IXHL with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from IXHL’s statements →

Incannex Healthcare Limited Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Sydney, NSW 2153 incannex.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$90K-31.6% 5y CAGRd
20112025
Net income
-$-46.88M
20112025
Free cash flow
-$-12.52M
20112025
Total equity
$13.4M+33.6% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$90K$10K$0.00$790K$1.9M
Operating income-$-23.79M-$-30.04M-$-20.53M-$-11.35M-$-11.43M
Net income-$-46.88M-$-18.46M-$-73.47M-$-14.9M-$-11.39M
EPSd-$-40.77M-$-3.42M-$-14.32M-$-1.5M-$-1.4M
Operating cash flow-$-12.51M-$-15.85M-$-16.18M-$-12.85M-$-6.87M
Capital expenditure-$-10K-$-280K-$-480K$0.00$0.00
Free cash flow-$-12.52M-$-16.12M-$-16.65M-$-12.85M-$-6.91M
Total assets$20.5M$17.1M$35.8M$38M$9.32M
Total debt$260K$370K$780K$0.00$0.00
Net debt-$-14.78M-$-5.49M-$-32.51M-$-37.63M-$-9.12M
Total equity$13.4M$11.2M$31.3M$36M$8.57M
Cash and short-term investments$15M$5.86M$33.3M$37.5M$9.12M
Income statement
20252024202320222021
Revenue$90K$10K$0.00$790K$1.9M
Cost of revenue$250K$100K$0.00$10K$910K
Gross profit-$-160K$10K$0.00$780K$990K
Research and development expenses$10.8M$19.3M$9.5M$5.37M$4.76M
Selling, general and administrative expenses$13.1M$25.6M$11.9M$10.2M$7.7M
Other expenses-$-250K-$-14.79M-$-900K-$-3.42M-$-40K
Operating expenses$23.6M$30.1M$20.5M$12.1M$12.4M
Cost and expenses$23.9M$30.1M$20.5M$12.2M$13.3M
Interest income$60K$310K$360K$10K$0.00
Interest expense$300K$0.00$0.00$0.00$0.00
Depreciation and amortization$250K$150K$130K$11.4M$7.64M
Ebitda-$-23.54M-$-27.7M-$-20.39M-$-16.54M-$-11.34M
Operating income-$-23.79M-$-30.04M-$-20.53M-$-11.35M-$-11.43M
Total other income/expenses, net-$-24.85M$180K-$-52.94M-$-3.55M$40K
Income before tax-$-48.64M-$-18.43M-$-73.47M-$-14.9M-$-11.39M
Income tax expense-$-1.76M$30K$0.00$0.00$0.00
Net income-$-46.88M-$-18.46M-$-73.47M-$-14.9M-$-11.39M
Weighted average shares outstanding$1.15M$5.39M$5.13M$9.93M$8.15M
Weighted average diluted shares outstanding$1.15M$5.39M$5.13M$9.93M$8.15M
Balance sheet
20252024202320222021
Cash and short-term investments$15M$5.86M$33.3M$37.5M$9.12M
Net receivables$4.63M$10M$290K$320K$170K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$20M$16.2M$34.6M$38M$9.32M
Property, plant and equipment, net$480K$840K$1.18M$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$480K$840K$1.18M$0.00$0.00
Total assets$20.5M$17.1M$35.8M$38M$9.32M
Accounts payable$6.07M$530K$2.63M$1.31M$230K
Short-term debt$180K$160K$170K$0.00$0.00
Deferred revenue$0.00$90K$0.00$0.00$0.00
Total current liabilities$6.98M$5.62M$3.84M$2.02M$760K
Long-term debt$70K$210K$610K$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$70K$210K$610K$0.00$0.00
Capital lease obligations$70K$370K$780K$0.00$0.00
Total liabilities$7.06M$5.83M$4.45M$2.02M$750K
Common stock$20K$0.00$0.00$86.6M$45.8M
Retained earnings-$-157.56M-$-110.67M-$-138.79M-$-59M-$-43.95M
Accumulated other comprehensive income (loss)-$-3.12M-$-3.33M-$-4.9M$0.00$6.62M
Total equity$13.4M$11.2M$31.3M$36M$8.57M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$260K$370K$780K$0.00$0.00
Net debt-$-14.78M-$-5.49M-$-32.51M-$-37.63M-$-9.12M
Cash flow statement
20252024202320222021
Net income-$-46.88M-$-18.46M-$-73.47M-$-14.9M-$-11.39M
Depreciation and amortization$250K$100K$130K$0.00$0.00
Stock-based compensation$2.61M$8.93M$3.23M$1.47M$600K
Change in working capital$6.78M-$-9.47M-$-940K$120K$10K
Accounts receivable$5.58M$0.00$0.00-$-90K$220K
Inventory$0.00$0.00$0.00$0.00$180K
Accounts payable$1.39M$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-12.51M-$-15.85M-$-16.18M-$-12.85M-$-6.87M
Investments in property, plant and equipment-$-10K-$-280K-$-480K$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$30K
Net cash used for investing activities-$-10K-$-280K-$-480K$0.00$30K
Common stock issued$47.5M$0.00$12.3M$43.4M$12.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$21.4M$0.00$12.3M$41.2M$12.3M
Net change in cash$9.18M-$-16.26M-$-5.59M$28.4M$5.8M
Cash at end of period$15M$5.86M$33.3M$37.6M$9.12M
Operating cash flow-$-12.51M-$-15.85M-$-16.18M-$-12.85M-$-6.87M
Capital expenditure-$-10K-$-280K-$-480K$0.00$0.00
Free cash flow-$-12.52M-$-16.12M-$-16.65M-$-12.85M-$-6.91M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Incannex Healthcare Limited

        Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.

        CEO
        Joel Bradley Latham
        Employees
        12
        Beta
        2.71

        Explore

        Frequently asked questions

        What is the intrinsic value of Incannex Healthcare Limited (IXHL)?

        InvestorsCraft does not currently publish an intrinsic value for IXHL. How the IC value is calculated.

        Is IXHL undervalued?

        InvestorsCraft does not publish an undervaluation signal for IXHL at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.